Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Sumitomo Pharma
Company

Sumitomo Pharma

Tracked across 1 events · 25 articles · First seen Feb 19, 2026 · Last active Mar 06, 2026

Sentiment
85
Attention
6
Events
1
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 85
Tech
Japan Approves First iPS Cell Therapies
Sumitomo Pharma obtained conditional approval for Amchepry, its Parkinson's disease treatment using iPS cells. This approval positions Sumitomo Pharma as a pioneer in the commercialization of iPS cell-derived therapies, potentially boosting its market standing and future revenue.
Feb 19, 2026 · 25 articles
Relationships (4)
Kyoto University research partner of ↔ Sumitomo Pharma Kyoto University researchers led trials for Sumitomo Pharma's Parkinson's treatm
Cuorips ↔ Sumitomo Pharma Unknown
Racthera partnered with ↔ Sumitomo Pharma Sumitomo Pharma partnered with Racthera Inc. for the development of Amchepry.
Shinya Yamanaka ↔ Sumitomo Pharma Unknown
NEWSDESK
Track Sumitomo Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.